Drug Profile
TAEST 16001
Alternative Names: Anti-NY-ESO-1 TCR transduced T cells; NY-ESO-1-specific TCR affinity enhancing specific T cell therapy; NY-ESO-1-transduced T-cells - Guangzhou-Pharmaceutical; TAEST-16001; TCR affinity enhancing specific T cell therapyLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Guangzhou Institute of Respiratory Disease
- Developer Axis Therapeutics; Guangdong Xiangxue Precision Medical Technology; Guangzhou Institute of Respiratory Disease; Guangzhou Xiangxue Pharmaceuticals; Sun Yat-Sen University; Xiangxue Life Science Research Center
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Soft tissue sarcoma
- No development reported Cancer; Non-small cell lung cancer; Osteosarcoma; Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Recurrent, Second-line therapy or greater) in China (IV, Infusion)